LABS — Life Science Reit Income Statement
0.000.00%
Last trade - 00:00- £139.30m
- £232.88m
- £19.94m
- 34
- 52
- 25
- 27
Annual income statement for Life Science Reit, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0.532 | 15.7 | 19.9 |
| Cost of Revenue | |||
| Gross Profit | — | 10.9 | 13.8 |
| Selling / General / Administrative Expenses | |||
| Total Operating Expenses | -7.2 | 42.6 | 34.5 |
| Operating Profit | 7.73 | -26.9 | -14.6 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | 7.74 | -27.5 | -21.9 |
| Provision for Income Taxes | |||
| Net Income After Taxes | 7.74 | -27.6 | -21.7 |
| Net Income Before Extraordinary Items | |||
| Net Income | 7.74 | -27.6 | -21.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | 7.74 | -27.6 | -21.7 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | 0.022 | -0.079 | -0.062 |
| Dividends per Share |